Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 06:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Welcomes Multiple Myeloma Leader Kenneth C. Anderson to its Scientific Advisory Board

TOLREMO therapeutics Welcomes Multiple Myeloma Leader Kenneth C. Anderson to its Scientific Advisory Board
October 17, 2025 05:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Completes First In Human Dose Escalation for TT125-802 and Presents Solid Tumor Monotherapy Results at ESMO 2025

Monotherapy shows deep and durable responses in NSCLC and a best-in-class safety profile without thrombocytopeniaCompletion of monotherapy dose escalation part of the study will be followed by the...
August 28, 2025 05:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Receives Two FDA Fast Track Designations for TT125-802 in Pretreated, Advanced or Metastatic NSCLC With Either an EGFR or a KRAS-G12C Mutation

TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung...
June 18, 2025 05:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Announces Strengthening of Leadership: Alessandra Cesano Joins Board of Directors, Florian D. Vogl Appointed Chief Medical Officer

Basel, Switzerland – June 18, 2025 - TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company developing TT125-802, a best-in-class CBP/p300 bromodomain inhibitor for the treatment of...
June 04, 2025 05:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Announces TT125-802 is the First CBP/p300 Bromodomain Inhibitor to Show Clinical Activity in Solid Tumors

- Deep and durable responses in drug-resistant KRAS-G12C- and EGFR-mutant NSCLC - Best-in-class safety profile highlights potential for development in combination to treat patients with...